🇪🇺 Elrexfio in European Union

EMA authorised Elrexfio on 7 December 2023

Marketing authorisation

EMA — authorised 7 December 2023

  • Application: EMEA/H/C/005908
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Elrexfio
  • Indication: Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
  • Pathway: conditional, PRIME
  • Status: approved

Read official source →

Elrexfio in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Elrexfio approved in European Union?

Yes. EMA authorised it on 7 December 2023.

Who is the marketing authorisation holder for Elrexfio in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.